PV-10 Elicits Hepatic Responses in Uveal Melanoma With Liver Metastases
Source: OncLive, November 2023
Treatment with the novel immunotherapy PV-10 led to hepatic responses in patients with metastatic uveal melanoma with liver metastases, according to updated data from a phase 1 trial.
Treatment with the novel immunotherapy PV-10 (rose bengal sodium) led to hepatic responses in patients with metastatic uveal melanoma with liver metastases, according to updated data from a phase 1 trial (NCT00986661).
Findings showed that evaluable patients (n = 25) experienced an objective response rate (ORR) in PV-10–injected hepatic lesions of 32%, including a complete response rate of 4% (n = 1) and a partial response rate of 28% (n = 7); 32% of patients (n = 8) achieved stable disease. The disease control rate was 64%.